Furthermore, all patients who had hepatotoxicity showed decreased AST/ALT and bilirubin (AST/ALT ≤5×ULN and bilirubin ≤1×UNL) after discontinuation of deferasirox. The gene discussed is GPT; the disease is hepatotoxicity.